Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Abbott and Teva Settle Patent Litigation Over Biaxin XL | Main | Maximizing Pharmaceutical Patent Life Cycles Conference October 23-25 in New York City »

August 08, 2006

Apotex Launches Generic Plavix At Risk

Apotex announced today that it has launched its generic version of Plavix.  Earlier this morning, MarketWatch reported that Bristol-Myers Squibb expected Apotex to launch its generic Plavix shortly.  Plavix, a blood thinner, is the second best selling pharmaceutical in the world, with $5.9 billion in annual sales.

Apotex is currently in patent litigation with Bristol-Myers Squibb and sanofi-aventis over its generic Plavix.  By launching its product before that litigation has been decided, Apotex is taking a huge risk that it will win the case.  If it loses, Apotex may be on the hook for billions of dollars in patent infringement damages.

Thanks to David Fischer of The Antitrust Review for alerting me to this news!

RELATED READING:

Posted by Aaron Barkoff in Paragraph IV Litigation |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.